Peptide Comparison

5-Amino-1MQvsTirzepatide

A small-molecule NNMT inhibitor studied in animals for fat loss and NAD+ metabolism.

The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.

Weight ManagementWeight Management

At a Glance

Quick
comparison

Dose Range

5-Amino-1MQ

N/A

Tirzepatide

5–10 mg

Frequency

5-Amino-1MQ

No human dose established

Tirzepatide

Once weekly

Administration

5-Amino-1MQ

Subcutaneous injection

Tirzepatide

Subcutaneous injection

Cycle Length

5-Amino-1MQ

8-12 weeks (community-reported; no human trial data)

Tirzepatide

Ongoing/indefinite

Onset Speed

5-Amino-1MQ

Not established in humans; gradual over weeks in animal studies

Tirzepatide

Moderate (1-2 weeks)

Evidence Level

5-Amino-1MQ

Preclinical only (animal and lab studies; no human trials)

Tirzepatide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

5-Amino-1MQ

Tirzepatide

Fat and weight reduction

5-Amino-1MQ75%

Tirzepatide0%

Metabolic markers

5-Amino-1MQ65%

Tirzepatide0%

NAD+ / cellular energy

5-Amino-1MQ60%

Tirzepatide0%

Human evidence

5-Amino-1MQ5%

Tirzepatide0%

Weight Loss

5-Amino-1MQ0%

Tirzepatide99%

Appetite Control

5-Amino-1MQ0%

Tirzepatide97%

Blood Sugar Control

5-Amino-1MQ0%

Tirzepatide96%

Technical Data

Compound
specifications

5-Amino-1MQ

Molecular Formula

C₁₀H₁₁N₂+ (cation); commonly supplied as the iodide salt (C₁₀H₁₁IN₂)

Molecular Weight

159.21 g/mol (cation); 286.11 g/mol (iodide salt)

Half-Life

Not established in humans; preclinical rodent data suggest a few hours (compound is membrane-permeable and orally active)

Bioavailability

Orally bioavailable in animal studies (high membrane permeability shown by PAMPA and Caco-2 assays); human data not established

CAS Number

42464-96-0 (salt form)

Tirzepatide

Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight

4813.45 g/mol

Half-Life

Approximately 5 days (120 hours)

Bioavailability

~80% (subcutaneous)

CAS Number

2023788-19-2

Protocols

Dosing
tiers

5-Amino-1MQ

standard

50 – 150 mg/day (community-reported, no trial)

Once daily, per community protocols

Undefined — no human study has run any duration

This is not a dose anyone established; it is the range people report using. The absence of human data here was checked rather than assumed: PubMed has no record under "5-amino-1MQ" and no clinical study of any NNMT inhibitor in people, ClinicalTrials.gov has no registered study of either the compound or the target, and no company has announced a clinical programme. The EU and WHO trial registries were not searched directly, so a trial registered only outside the US cannot be ruled out. With no human trial, there is no human safety data and no established human maximum, so there is nothing to describe any of these figures as tolerated against. It is shown as a single range rather than as starting, standard and advanced steps because no study set those steps — whether people using it escalate through them is a question about community practice that has not been checked here. The numbers that do exist are animal data only and do not convert to a human dose: mice received about 34 mg/kg a day by subcutaneous injection, 20 mg/kg three times daily for 11 days, n=9 [1]. In a dose-escalation study spanning 10 to 150 mg/kg/day, 60 mg/kg/day produced no observable adverse effects — in TWO mice [1]. Lab screening found off-target monoamine oxidase-A inhibition at higher concentrations, so caution with MAO-sensitive drugs and foods is reasonable [2], and the compound is cytotoxic to cultured pre-adipocytes at high concentration — about 40% loss of viability at 600 µM against none at 10 µM [1].

Tirzepatide

starting

2.5 mg

Once weekly

First 4 weeks

FDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.

standard

5-10 mg

Once weekly

Increase by 2.5 mg after at least 4 weeks at each dose

Per FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].

advanced

12.5-15 mg

Once weekly

Ongoing maintenance

15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].

Applications

Best
suited for

5-Amino-1MQ

Fat loss research

The clearest, most repeated finding: obese mice lost body weight and fat mass on 5-Amino-1MQ without eating less [1][2]. This is the main reason people are interested — though it is animal data, not human proof.

Metabolic health support

In mice, it improved blood sugar, insulin, and liver fat [2]. Researchers see NNMT inhibition as a promising angle for metabolic syndrome [4].

NAD+ and cellular energy science

By blocking NNMT, it raises NAD+ and SAM inside cells, which supports how cells make and use energy [1][4]. This makes it interesting to people studying aging and metabolism.

Tirzepatide

People Who Want Maximum Weight Loss Results

If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].

Those Who Haven't Succeeded with Semaglutide

Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].

People with Type 2 Diabetes Needing Aggressive Control

Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].

Individuals Looking to Transform Their Relationship with Food

Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].

Safety Profile

Side
effects

5-Amino-1MQ

Common

No verified human side effects
Mild nausea or headache (community-reported)

Uncommon

Fatigue or flushing (community-reported)

Serious

Possible off-target MAO-A effects (theoretical)
Unknown long-term and human risks

Tirzepatide

Common

Nausea
Diarrhea
Decreased Appetite
Vomiting

Uncommon

Gallbladder Problems
Hair Thinning (Telogen Effluvium)

Serious

Pancreatitis
Thyroid Tumors (Theoretical Risk)

Research Status

Safety
& evidence

5-Amino-1MQ

Evidence Level

Preclinical only (animal and lab studies; no human trials)

FDA Status

Research compound — not FDA approved

Safety Overview

The honest picture: nobody has run a human safety trial on 5-Amino-1MQ, so everything below is from mice and cultured cells. In the 11-day mouse study, 9 treated animals lost 2.0 ± 0.6 g of body weight (about 5.1% from baseline) while 9 controls gained 0.6 ± 0.4 g, with no difference in food intake and no observable adverse effects reported [1]. The tolerability ceiling people quote comes from a dose-escalation study spanning 10 to 150 mg/kg/day in TWO mice, where 60 mg/kg/day produced no observable adverse effects [1] — a denominator worth seeing before treating it as a safety margin. In cultured pre-adipocytes the compound is cytotoxic at high concentration: no effect on viability at 10 µM, modest cytotoxicity from 100 to 300 µM, and roughly 40% loss of viability at 600 µM [1]. Lab screening also found off-target inhibition of monoamine oxidase-A at higher concentrations [2]. Short studies in mice cannot rule out problems that appear over months or years in people. Treat this as an experimental compound and talk to a doctor first, particularly if you take any medication.

Contraindications

xNo human safety data exists — all evidence is from animals and lab work
xPregnancy or breastfeeding
xUse with MAO-A-sensitive medications, given off-target MAO-A inhibition seen in lab screening [2]

Tirzepatide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]

Contraindications

xPersonal or family history of medullary thyroid carcinoma (MTC)
xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
xCurrent or recent pancreatitis
xPregnancy or planning to become pregnant

Decision Guide

Which is
right for you?

Choose 5-Amino-1MQ if...

Fat loss (research context)
Metabolic health support
NAD+ and cellular energy metabolism

Choose Tirzepatide if...

Maximum weight loss results
Long-term obesity management
Type 2 diabetes control
Metabolic health improvement

Full 5-Amino-1MQ Profile Full Tirzepatide Profile

Peptide Database

Quickcomparison

Benefitratings

Compoundspecifications

Dosingtiers

Bestsuited for

Sideeffects

Safety& evidence

Which isright for you?

Quick
comparison

Benefit
ratings

Compound
specifications

Dosing
tiers

Best
suited for

Side
effects

Safety
& evidence

Which is
right for you?